Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec 7:38:100465.
doi: 10.1016/j.jbo.2022.100465. eCollection 2023 Feb.

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer

Marsha M van Oostwaard  1   2 , Joop P van den Bergh  1   2 , Yes van de Wouw  1 , Maryska Janssen-Heijnen  3   4 , Marc de Jong  5 , Caroline E Wyers  1
Affiliations

High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer

Marsha M van Oostwaard et al. J Bone Oncol. .

Abstract

Purpose: Treatment of Prostate Cancer (PCa) with Androgen Deprivation Therapy (ADT) involves long-term consequences including bone loss and fractures. Our aim was to evaluate the calculated fracture risk and the prevalence of osteoporosis, vertebral fractures (VF) and sarcopenia in men with PCa at initiation of ADT, as ADT will increase fracture risk from that moment onward.

Methods: In this cross-sectional real-world study in men at ADT initiation, fracture risk factors including comorbidities, medication, and 10-year fracture risk (FRAX®) were assessed. Laboratory tests, dual-energy X-ray absorptiometry, and spinal X-rays were performed. Sarcopenia was defined according to EWGSOP2.

Results: In 115 men at ADT initiation, aged 73.3 (±7.6) years, osteoporosis was diagnosed in 4.3 % and osteopenia in 35.7 %. The mean 10-year fracture risk of major osteoporotic fracture was 4.4 % and of hip fracture 1.7 %, respectively. At least one VF was present in 32.2 % and 33.9 % of men had osteoporosis and/or a VF assessed on spinal X-rays. In 10.4 % at least one new fracture-risk-associated metabolic bone disorder was diagnosed with laboratory testing. Sarcopenia was diagnosed in only one patient.

Conclusions: Although the prevalence of osteoporosis, sarcopenia and 10-years fracture risk is low, there is a high prevalence of vertebral fractures in a third of the men with PCa at the time of ADT initiation. Besides a BMD measurement and fracture risk calculation using FRAX, a systematic vertebral fracture assessment should be considered in all men with PCa at initiation of ADT to provide a reliable baseline classification of VFs to improve identification of true incident VFs during ADT.

Keywords: ADT, Androgen deprivation therapy; Androgen deprivation therapy; BMD, Bone mineral density; Fracture risk; Osteoporosis; PCa, Prostate cancer; Prostate cancer; Sarcopenia; VF, Vertebral fracture; Vertebral fractures.

PubMed Disclaimer

Conflict of interest statement

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Marsha van Oostwaard, Dr. Yes van de Wouw, Professor dr. Maryska Janssen-Heijnen, Dr. Marc de Jong and Dr. Caroline Wyers have no conflicts of interest. Professor dr. Joop van den Bergh reports consulting fees and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Amgen institution and UCB institution outside the submitted work.

Figures

Fig. 1
Fig. 1
Distribution of prevalent vertebral fractures in men with PCa at initiation of ADT.
See this image and copyright information in PMC

References

    1. IKNL Nederlandse Kankerregistratie (NKR). https://iknl.nl/nkr-cijfers Accessed 01-04-2022 2022.
    1. Shahinian V.B., Kuo Y.F., Freeman J.L., Orihuela E., Goodwin J.S. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103:1615–1624. doi: 10.1002/cncr.20955. - DOI - PubMed
    1. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of fracture after androgen deprivation for prostate cancer. N. Engl. J. Med. 2005;352:154–164. doi: 10.1056/NEJMoa041943. - DOI - PubMed
    1. Alibhai S.M., Duong-Hua M., Cheung A.M., Sutradhar R., Warde P., Fleshner N.E., Paszat L. Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J. Urol. 2010;184:918–923. doi: 10.1016/j.juro.2010.04.068. - DOI - PubMed
    1. Abrahamsen B., Nielsen M.F., Eskildsen P., Andersen J.T., Walter S., Brixen K. Fracture risk in Danish men with prostate cancer: a nationwide register study. BJU Int. 2007;100:749–754. doi: 10.1111/j.1464-410X.2007.07163.x. - DOI - PubMed

LinkOut - more resources